-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Phase II KarMMa trial evaluated the efficacy and safety of CAR-T cell therapy targeted by the B cell maturation antigen (BCMA) of bluebird bio and Bristol Myers Squibb .
CAR-T immunity
The KarMMa study reached the primary endpoint of overall response rate and the key secondary endpoint of complete response rate.
The data showed that triple-exposed RRMM patients (n = 128) received ide-cel treatment to produce a deep and long-lasting response.
In the KarMMa study, ide-cel is consistent with the known toxicity of CAR-T cell therapy, regardless of the dose level.
Original source:
Original source:https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here